MetaStat, Inc. (OTCMKTS:MTST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
MetaStat, Inc. (OTCMKTS:MTST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective May 3, 2017, in connection with a restructuring of the board of directors of MetaStat, Inc. (the “Company”), each of Dr. Oscar Bronsther, Richard Berman and H. Philip Goodeve resigned from the board of directors effective immediately. The resignations of Messrs. Bronsther, Berman and Goodeve were not due to any disagreements on any matter relating to the Company’s operations, policies or practices.
Additionally, Jerome B. Zeldis, M.D., Ph.D. was promoted from Vice Chairman to Chairman of the board of directors, and Douglas A. Hamilton, the Company’s President and Chief Executive Officer, was appointed to the board of directors. The Company will undertake a formal search to appoint new qualified independent directors to its board of directors and board committees as soon as practical.
About MetaStat, Inc. (OTCMKTS:MTST)
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company’s platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate. MetaStat, Inc. (OTCMKTS:MTST) Recent Trading Information
MetaStat, Inc. (OTCMKTS:MTST) closed its last trading session 00.00 at 1.15 with 5,002 shares trading hands.
MetaStat, Inc. is a pre-commercial molecular diagnostic company focused on the development and commercialization of diagnostics to provide oncologists and patients with clinically actionable information regarding the risk of systemic metastasis and adjuvant chemotherapy treatment decisions. The Company’s platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. It is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate. MetaStat, Inc. (OTCMKTS:MTST) Recent Trading Information
MetaStat, Inc. (OTCMKTS:MTST) closed its last trading session 00.00 at 1.15 with 5,002 shares trading hands.
